Proactive investorsLogo Proactive Investors UK Website

Search field
Additional information
Additional Information
Market: TSX-V
Sector: Medical
Epic: TSX-V:TMD
News: Latest news
Web Site: Titan Medical Inc
Other Articles: 19-11-2008

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday March 11, 11:17Eco Animal Health Group: moves into US and China could be transformational

Aivlosin® now accounts for more than half of global sales for ECO. Sales in China during FY 2009 were more than 60% ahead of the previous year, and expectations for FY 2010 indicate similar progress.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Friday March 12, 01:39Circadian Technologies to present at Ultimate Healthcare & Biotechnology Event, March 24

Robert Klupacs, CEO of Circadian Technologies, recommended by US Investment Bank Merriman Curhan Ford, as "the Cheapest Little Antibody Company on the Planet" will present in Sydney.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Tuesday March 09, 10:55Nidec Corporation adds third factory and laboratory in Dalian City, China

Nidec Corporation (NYSE:NJ), the Japan headquartered manufacturer of small-to-mid-size motors, fan motors, and pivot assemblies, is to expand its presence in China through the construction [...]

FULL ARTICLE ►
Titan Medical Inc

Titan Medical Inc

Titan Medical focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus(R), a next generation 4-armed robotic surgical system, with the objective of enabling surgeons to remotely manipulate surgical instruments.
Tuesday, March 17, 2009

Titan Medical and Bell Canada in successful telesurgery tests over 7,000 km

company news image

Titan Medical Inc Bell Canada announced they have successfully completed long-distance telesurgery tests using Titan's Phase B Amadeus robotic surgical system. Telesurgery is the performance of robotic surgery over a distance using a communication link.

During a one-week period, the tests were done over a roundtrip from Toronto to Vancouver, with a total communications distance of approximately 7,000 kilometres.

Transmitting low latency dual high definition signals for three dimensional vision and instrument commands with minimal time lag, or latency, were critical. Total end-to-end latency was approximately 300 milliseconds, and will be expected to shorten when the Phase C clinical testing platform is completed, the companies said.

Research has shown that 350 ms or less latency is required for surgeons to effectively perform telesurgery. Additionally, the amount of bandwidth needed to transmit the high definition video is being analyzed.

The extreme distances in these tests were implemented to generate worst-case scenario data. "In day-to-day applications, we expect the distances to be much shorter. These will likely be between neighbouring cities, a tertiary hospital catchment area or proximate offshore locations," commented Titan Medical president Dr Reiza Rayman.

Titan Medical in November 2009 announced a deal with Bell Canada's Health unit to develop, integrate and service telesurgery capabilities for Amadeus, a next generation robotic surgical system being developed to perform keyhole robotic minimally invasive surgery.

AddThis Feed Button
Register here to be notified of future Titan Medical Inc articles.

Investors interested in Titan Medical Inc recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.